PredictAR™ is an expanded comprehensive pharmacogenomics report providing guidance for over 120 medications. PredictAR™ utilises the analysis of 18 genes, all of which play a role in the way patients respond to various medications.
Genes Tested
ABCB1, ABCC1, ABCG2, COMT, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, NUDT15, OPRM1, TPMT, SLCO1B1, UGT1A1, VKORC1
Clinical Specialties Benefited by PredictARTM Testing
Cardiology, Gastroenterology, General Practice, Haematology, Infectious Disease, Neurology, Oncology, Pain management, Psychiatry, Rheumatology, Transplantation, others
Result TAT
3-4 business days from receipt of sample
PredictARTM Test Report
Easily understood report that provides evidence-based expert recommendation by CPIC, FDA and DPGW.
PredictARTM provides both dosing suggestions and medication avoidance alerts. This information in-conjunction with clinical parameters, can be used by clinicians to ensure every patient receives a more personalised approach to medication selection.
Benefits of PredictARTM Pharmacogenomic Testing
- Up to 30% reduction in unwanted adverse drug reactions
- Improved medication efficacy
- Improved patient medication compliance
Add Specific HLA Markers to Your PredictARTM Report
Incite Genomics also provides PredictAR-plus, a test panel that contains all genes analysed in PredictARTM but with the addition of specific HLA markers (HLA-B *15:02, *57:01, *58:01). Please note that the result TAT for PredictAR-plus is 7-9 days from sample receipt due to multiple technology platforms applied.